Safety Assessment of EPA-Rich Polar Lipid Oil Produced From the Microalgae Nannochloropsis oculata

• Published in: International journal of toxicology 2014-11, Vol.33 (6), p.459-474
• Main Authors: Kagan, Michael L., Sullivan, Dexter W., Gad, Shayne C., Ballou, Corey M.
• Format: Article
• Language: English
• Subjects: Animals; CHO Cells; Chromosome Aberrations; Cricetulus; Eicosapentaenoic Acid - toxicity; Erythrocytes - drug effects; Escherichia coli - drug effects; Escherichia coli - genetics; Female; Male; Maximum Tolerated Dose; Microalgae; Mutagenicity Tests; No-Observed-Adverse-Effect Level; Oils - toxicity; Rats, Sprague-Dawley; Salmonella typhimurium - drug effects; Salmonella typhimurium - genetics; Stramenopiles; Toxicity Tests, Subacute; Toxicity Tests, Subchronic
• ISSN: 1091-5818; 1092-874X
• DOI: 10.1177/1091581814553453

Almega PL is an eicosapentaenoic acid-rich ω-3 oil that is isolated from Nannochloropsis oculata algae and developed as a dietary supplement. The safety of the algal oil was evaluated in 14- and 90-day studies in Sprague-Dawley rats by oral gavage at dose levels of 0, 250, 500, and 2500 mg/kg/d and 0, 200, 400, and 2000 mg/kg/d, respectively. No mortalities occurred and no signs of toxicity were observed during the studies. No treatment-related effects were seen for body weight, food consumption, ophthalmology, neurological effects, urinalysis, clinical pathology, gross pathology, organ weights, or histopathology. Although statistically significant effects were noted for some end points, none were considered to be of toxicological significance. The no observed adverse effect level for Almega PL was 2000 mg/kg/d. Additionally, Almega PL was not mutagenic in Salmonella typhimurium or Escherichia coli, did not induce chromosome aberrations in Chinese hamster ovary cells, and did not induce genotoxic effects in vivo in rat bone marrow erythrocytes.